The most frequent genetic lesions target the negative regulators of the canonical NF-κB pathway TNFAIP3 and NFKBIA (encoding A20 and IĸBα) in 40% or 20% of cHL cases, respectively [4,5,6,12,17]. This evidence concerns the gene NFKB1 and classic Hodgkin lymphoma.